Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity.
Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily x 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.
Nanus
D M
DM
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY.
Kelsen
D P
DP
Lipperman
R
R
Eisenberger
M
M
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D007069:Ifosfamide